SCHEMBL6983496

SCHEMBL6983496

CC(C)[C@@H](NS(=O)(=O)c1ccc(F)cc1)C(=O)ON1C(=O)CCC1=O

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 8/20 0.55
MMP13 P45452 8/20 0.55
MMP9 P14780 8/20 0.55
MMP3 P08254 7/20 0.55
MMP1 P03956 6/20 0.55
MMP7 P09237 6/20 0.55
ADAMTS4 O75173 4/20 0.47
CAPN1 P07384 1/20 0.47
SLC1A3 P43003 1/20 0.45
SLC1A2 P43004 1/20 0.45
SLC1A1 P43005 1/20 0.45
MMP14 P50281 2/20 0.43
CA12 O43570 1/20 0.43
CA7 P43166 1/20 0.43
CA9 Q16790 1/20 0.43
CA14 Q9ULX7 1/20 0.43
MMP8 P22894 2/20 0.43
LMNA P02545 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3843452 1.00 MMP2 (0.55) MMP2MMP13MMP9MMP3MMP1
SCHEMBL6986036 0.88 MMP2 (0.55) MMP2MMP13MMP9MMP3MMP1
SCHEMBL6978976 0.82 SLC1A3 (0.49) MMP2MMP13MMP9MMP3MMP1
SCHEMBL7315740 0.80 MMP2 (0.70) MMP2MMP13MMP9MMP3MMP1
SCHEMBL14943559 0.78 MMP2 (0.71) MMP2MMP13MMP9MMP3MMP1
SCHEMBL6801083 0.77 MMP2 (0.63) MMP2MMP13MMP9MMP3MMP1
SCHEMBL6800548 0.77 MMP2 (0.63) MMP2MMP13MMP9MMP3MMP1
SCHEMBL2161562 0.75 MMP2 (0.91) MMP2MMP13MMP9MMP3MMP1
SCHEMBL3842066 0.75 MMP2 (0.91) MMP2MMP13MMP9MMP3MMP1
SCHEMBL6797666 0.75 MMP2 (0.91) MMP2MMP13MMP9MMP3MMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0927716-B1 Angiogenesis inhibitor SENJU PHARMA CO (JP) 2003-05-07 EP disclosed
US-6551999-B1 For therapy and prophylaxis of angiogenesis associated with wound healing, inflammation, growth of tumor and the like; angiogenesis as seen in diabetic retinopathy, prematurity retinopathy, retinal venous occlusion, metastasis of tumors SENJU PHARMACEUTICAL CO., LTD. (JP) 2003-04-22 US disclosed
EP-0771565-B1 Angiogenesis inhibitor SENJU PHARMA CO (JP) 2003-01-02 EP disclosed
US-6214800-B1 ANGIOGENESIS INHIBITORS SENJU PHARMACEUTICAL CO., LTD. (JP) 2001-04-10 US disclosed
US-6057290-A ADMINISTERING A CYSTEINE PROTEASE INHIBITOR TO A PATIENT FOR INHIBITING ANGIOGENESIS SENJU PHARMACEUTICAL CO., LTD. (JP) 2000-05-02 US disclosed
EP-0928786-A1 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1999-07-14 EP disclosed
EP-0927716-A1 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1999-07-07 EP disclosed
EP-0771565-A2 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1997-05-07 EP disclosed